The Protective Effect of Azelnidipine for the Prevention of Heart Fibrosis Occurrence on Balb/c Mice with Iron Overload

Sarosa, Hadi; Bahrudin, Udin; Soemantri, Augustinus; Muis, Siti Fatimah; Arfian, Nur; Hisatome, Ichiro

doi:10.3329/bjms.v19i2.44999

Cited by 2 publications

(4 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The research conducted by Sangartit (2016) explained that iron sucrose through I.P.injection increased iron serum, ferritin, transferrin saturation (TfSat), and Non transferrin bound iron (NTBI) level 29 . Iron sucrose administration through I.P injection increased TGF β level and fibrosis in the heart 11 . Oral administration of iron supplement (FeSO 4 ) did not increase NTBI level 30 .…”

Section: Discussionmentioning

confidence: 92%

“…Iron sucrose can be administered intraperitoneally for extra iron tests in mice 11,32 . Mice administered with IS 50 mg/kg intraperitoneally 2 times a week increased iron deposit in the liver, lien, and bone marrow 43 .…”

Section: Discussionmentioning

confidence: 99%

“…Besides due to chronic hepatitis virus and non-alcoholic fatty liver disease (NAFLD), over onethird of chronic liver disease cases are caused by iron accumulation. Administration of iron sucrose at a dose of 1.5 mg intra peritoneal injection intermittently initiates fibrosis in mouse's heart 11 . Iron overload also triggers inflammation and apoptosis in mouse's pancreatic cells administered with 180 mg/kg of iron 12 .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The effectiveness of deferasirox to prevent from the occurrence of liver fibrosis in balb/c mice with iron overload

Sarosa

Wajiih

Indrayani

2023

Bangladesh J Med Sci

View full text Add to dashboard Cite

Background: Oxidation of hepatocyte mitochondria due to iron overload led to hepatocyte injury, elevated Transforming growth factor- β (TGF- β), and fibrosis. Fibrosis starts with stellate cell fibrogenesis activated by chronic hepatocyte injury. Liver fibrosis is the main cause of morbidity and mortality in iron overload. Deferasirox is an iron chelation drug serving to bind iron overload and have an antifibrotic effect. Aim: To examine the effect of deferasirox on liver fibrosis prevention due to iron overload. Methods: This experimental research used a post-test only control group design on male Balb/c mice that were randomly divided into 3 groups, each n=5. Group 1 (NaCl+S) was administered with 0.3 cc Na Cl 0.9% through intra peritoneal (I.P) injection and drug solvent (Aquabidest, CMC and Nipagin) per oral (P.O) intermittently. Group 2 (Fe+S) was administered with 0.3 cc 1.5 mg Fe+sucrose (Venofer®) through I.P injection and drug solvent (Aquabidest, CMC and Nipagin) P.O intermittently. Group 3 (Fe+Dfx) 0.3 cc 1.5 mg Fe+sucrose (Venofer®) I.P injection, and deferasirox 20 mg/kgBW/day P.O intermittently. All of the treatments were given for 60 days. The fibrosis area fraction of the liverwas assessed using software ImageJ. Results: The average fibrosis area fraction of group 1 was 0.00 ± 0.00%, group 2 was 9.17 ± 8.54% and group 3 was 1.38 ± 0.20%. The fibrosis area fractions between groups 2 and 3 were significantly different with p value 0.000 (p<0.05). The body weight of group 2 was higher than that of groups 3 and 1. Conclusions: Iron overload causes liver fibrosis in male Balb/c mice. Deferasirox administration may lower the area of liver fibrosis in male Balb/c mice due to iron overload. Bangladesh Journal of Medical Science Vol. 22 No. 01 January’23 Page : 84-90

show abstract

Section: Discussionmentioning

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The effectiveness of deferasirox to prevent from the occurrence of liver fibrosis in balb/c mice with iron overload

Sarosa

Wajiih

Indrayani

2023

Bangladesh J Med Sci

View full text Add to dashboard Cite

show abstract

“…Patients with β-thalassemia demand permanent iron chelation therapy to prevent complications relatedtotransfusional iron overload [1,3] .During recent years, Deferasiroxhas been widely used as efficaciousiron chelation treatmentfor patients at least 2 years of age. [4,5] .…”

Section: Introductionmentioning

confidence: 99%

Changes of liver transaminases levels during one year follow up of Deferasirox treatment in children with β-thalassemia major

Hafidh¹,

Younis²

2020

Bangladesh J Med Sci

View full text Add to dashboard Cite

Objectives: Abnormal liver function tests lead to interruptions of Deferasirox therapy. The aim of this study is to determine the changes in liver transaminases levels in pediatric patients with β -thalassemia major during one year follow up of Deferasirox treatment. Material and methods: This study was conducted at Ibn Al Atheer center of thalassemia, Mosul city, Iraq during the period from 3rd of February 2013 till 2nd of February 2014. Seventy one pediatric patients with β -thalassemia major were included in the study. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured every 4 weeks after starting Deferasirox therapy dose of 30 mg /kg/day for one year. Results: In comparison to mean baseline ALT values, there were significant elevations of mean ALT values in each of the subsequent 4-weekly interval readingsafter Deferasirox therapy. There was nearly eleven times relative risk of having ALT ≥ 5 upper normal level (UNL) in patient with abnormal baseline ALT (Odd ratio 10.96,95% Confidence Interval: lower 2.05, upper 58.58). During a year of study, Deferasirox therapy was associated withALT readings of ≥ 5UNL in 22(31%) of pediatric β-thalassemia patients and that elevation lasted for 4 weeks in 95.5% of patients. Conclusions: Elevated ALT of ≥ 5UNL after Deferasirox therapy was short- lived, and lasted for 4 weeks in 95.5% of patients. It is advisable to start Deferasirox therapy at a dose of 30 mg /kg / day when baseline ALT level is normal. Bangladesh Journal of Medical Science Vol.19(3) 2020 p.453-457

show abstract

The Protective Effect of Azelnidipine for the Prevention of Heart Fibrosis Occurrence on Balb/c Mice with Iron Overload

Cited by 2 publications

References 26 publications

The effectiveness of deferasirox to prevent from the occurrence of liver fibrosis in balb/c mice with iron overload

The effectiveness of deferasirox to prevent from the occurrence of liver fibrosis in balb/c mice with iron overload

Changes of liver transaminases levels during one year follow up of Deferasirox treatment in children with β-thalassemia major

Contact Info

Product

Resources

About